唑来膦酸联合靶向及免疫调节药物的抗肿瘤研究进展

Progress of Zoledronic Acid Combined with Targeted or Immunomodulatory Drugs in Antitumor Research

唑来膦酸是第三代含氮双磷酸盐,在临床中广泛用于治疗骨疾病。既往研究发现唑来膦酸在体内外对多种肿瘤细胞均有抗肿瘤作用,同时可以协同增加化疗、内分泌治疗、放疗等抗肿瘤疗效。最近研究发现,唑来膦酸亦可以协同增加靶向及免疫调节药物的抗肿瘤疗效,其抗肿瘤作用机制与抑制甲羟戊酸代谢途径、影响肿瘤信号通路、调节免疫反应、抗血管生成等有关。本文综述了唑来膦酸联合靶向及免疫调节药物在抗肿瘤治疗方面的研究进展。

Zoledronic acid(ZA) is the third generation of nitrogen-containing bisphosphonates and widely used in the treatment of bone disease in clinic. Previous studies have found that zoledronic acid have antitumor effect in a variety of tumor cells in vitro and in vivo. Meanwhile, it can increase the antitumor effect of its combination with chemotherapy, endocrine therapy and radiation therapy. Recent studies have found that zoledronic acid also can be coordinated to increase the antitumor effect of targeted and immunomodulatory drugs. Its antitumor mechanism includes inhibiting mevalonate pathway, influencing tumor signaling pathways, regulating immune response, anti-angiogenesis and so on. This review collects the latest information about zoledronic acid combined with targeted and immunomodulatory drugs in antitumor therapy.